Back to search

Article

Direct β1/ β2 AMPK activation reduces liver steatosis but not fibrosis in a mouse model of non-alcoholic steatohepatitis

2024-06-02

Abstract excerpt

5’AMP-activated protein kinase (AMPK) activators show potential for treating Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) due to their inhibiting effects on fatty acid and cholesterol synthesis. The absence of treatments for NASH, and its propensity for progression to severe disease, lead us to identify and characterize BI9774, a small molecule AMPK activator, which we used to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bed9e296-dc17-5bf8-86f9-e54e4d306a86
DOI
10.1101/2024.05.30.596624
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Direct β1/ β2 AMPK activation reduces liver steatosis but not fibrosis in a mouse model of non-alcoholic steatohepatitisDOI 10.1101/2024.05.30.596624
Select a neighboring publication to make it the new centre.